BMC Medicine201210:107
https://doi.org/10.1186/1741-7015-10-107© Katchanov and Birbeck; licensee BioMed Central Ltd. 2012
Received: 10 July 2012Accepted: 24 September 2012Published: 24 September 2012
In 2011, the World Health Organization’s (WHO) mental health Gap Action Programme (mhGAP) r...eleased evidence-based epilepsy-care guidelines for use in low and middle income countries (LAMICs). From a
geographical, sociocultural, and political perspective, LAMICs represent a heterogenous group with significant differences in the epidemiology, etiology, and perceptions of epilepsy. Successful implementation of
the guidelines requires local adaptation for use within individual countries. For effective implementation and sustainability, the sense of ownership and empowerment must be transferred from the global health authorities to the local people. Sociocultural and financial barriers that impede the implementation of the guidelines should be
identified and ameliorated. Impact assessment and program revisions should be planned and a budget allocated to them. If effectively implemented, as intended, at the primary-care level, the mhGAP
guidelines have the potential to facilitate a substantial reduction in the epilepsy treatment gap and improve the quality of epilepsy care in resource-limited settings.
more
The WHO Global Burden of Disease (GBD) study measures the burden of
disease using the disability-adjusted life year metric (DALY). The DALY metric
was developed to assess the burden of disease consistently across diseases,
risk factors and regions. A consistent and comparative description of the ...burden
of diseases and injuries and the risk factors that cause them is important as it
can inform health decision-making and health care planning.
more
Int J Crit Illn Inj Sci. 2012 May-Aug; 2(2): 82–97.
doi: 10.4103/2229-5151.97273
PMCID: PMC3401822
PMID: 22837896
www.jogh.org • doi: 10.7189/jogh.02.020405 ~ December 2012 • Vol. 2 No. 2 • 020405
Bulletin de l'Organisation mondiale de la Santé 2012;90:871-871A. doi: 10.2471/BLT.12.113183
Bulletin de l'Organisation mondiale de la Santé Numéros précédents Volume 90: 2012 Volume 90, Numéro 12, décembre 2012, 869-944
Q3: Are pharmacotherapies safe and effective for the treatment of psychostimulant dependence (maintenance or relapse prevention) in non-specialized settings?
This publication is intended for professionals training or practicing in mental health and not for the general public. The opinions expressed are those of the authors and do not necessarily represent the views of the Editor or IACAPAP. This publication seeks to describe the best treatments and pract...ices based on the scientific evidence available at the time of writing as evaluated by the authors and may change as a result of new research. Readers need to apply this knowledge to patients in accordance with the guidelines and
laws of their country of practice. Some medications may not be available in some countries and readers should consult the specific drug information since not all dosages and unwanted effects are mentioned. Organizations, publications and websites are cited or linked to illustrate issues or as a source of further information. This does not mean that authors, the Editor or IACAPAP endorse their content or
recommendations, which should be critically assessed by the reader. Websites may also change or cease to exist.
more
Q1: What are the effective maternal mental health interventions to prevent developmental problems in early infancy?
Q1: Are brief psychosocial interventions for people using cannabis or psychostimulants effective in reducing drug use, dependence and harm from drug use?
Assessing and improving quality and human rights in mental health and social care facilites
Q 6. Does the provision of sterile injection equipment to injecting drug users reduce injecting related harm? Is advice on ways to reduce drug related harm safe and effective, using an outreach model of service delivery?
Q2: What interventions are safe and effective for drug withdrawal (cannabis, amphetamines, cocaine, benzodiazepines, and inhalants)?
Miscellaneous
Chapter J.3
Miscellaneous
Child and adolescent psychiatric emergencies
Chapter J.1
Miscellaneous
Chapter J.2
Externalizing disorders
Chapter D.1
Attention deficit hyperactivity disorder